Equities analysts expect InVitae Corp (NYSE:NVTA) to report ($0.57) earnings per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for InVitae’s earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.70). InVitae reported earnings of ($0.69) per share in the same quarter last year, which indicates a positive year over year growth rate of 17.4%. The firm is expected to announce its next earnings report on Monday, February 12th.
On average, analysts expect that InVitae will report full year earnings of ($2.47) per share for the current financial year, with EPS estimates ranging from ($2.58) to ($2.30). For the next year, analysts expect that the company will report earnings of ($1.75) per share, with EPS estimates ranging from ($1.99) to ($1.38). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover InVitae.
A number of research analysts recently commented on NVTA shares. BidaskClub upgraded InVitae from a “hold” rating to a “buy” rating in a research report on Thursday, October 12th. Zacks Investment Research cut InVitae from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, Leerink Swann decreased their price target on InVitae from $14.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $13.50.
Shares of InVitae (NYSE:NVTA) traded down $0.46 during midday trading on Tuesday, hitting $9.08. The company had a trading volume of 289,532 shares, compared to its average volume of 142,075. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.33. InVitae has a 52 week low of $2.60 and a 52 week high of $9.67. The company has a market capitalization of $506.69, a PE ratio of -3.55 and a beta of 1.30.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Verity Asset Management Inc. boosted its stake in InVitae by 0.8% in the second quarter. Verity Asset Management Inc. now owns 10,607 shares of the medical research company’s stock valued at $101,000 after buying an additional 81 shares in the last quarter. Lakeview Capital Partners LLC acquired a new stake in InVitae in the third quarter valued at about $117,000. Gabelli Funds LLC acquired a new stake in InVitae in the third quarter valued at about $131,000. State Board of Administration of Florida Retirement System acquired a new stake in InVitae in the third quarter valued at about $133,000. Finally, CAPROCK Group Inc. acquired a new stake in InVitae in the third quarter valued at about $139,000. Institutional investors own 64.67% of the company’s stock.
WARNING: “-$0.57 Earnings Per Share Expected for InVitae Corp (NVTA) This Quarter” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/13/0-57-earnings-per-share-expected-for-invitae-corp-nvta-this-quarter.html.
InVitae Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Get a free copy of the Zacks research report on InVitae (NVTA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.